



Correction to: Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?

Rosa Ahn¹ · Vinay Prasad^{2,3,4}

Published online: 1 October 2018
© Springer Science+Business Media, LLC, part of Springer Nature 2018

Correction to: Cardiovasc Drugs Ther
<https://doi.org/10.1007/s10557-018-6830-x>

The original version of this article unfortunately contained a mistake. There was a typo in the second sentence of the paragraph under the section **Was the Dose of Drugs Fair?**—"320 mg twice a day" should read "160 mg twice a day".

The corrected paragraph is shown below.

Was the Dose of Drugs Fair?

PARADIGM-HF enrolled 10,521 patients, of whom 8442 (80.2%) underwent randomization. Of those, 4187 subjects were randomly assigned to sacubitril/valsartan (at a dose of valsartan 160 mg twice a day, the maximum FDA-approved dose), and 4212 were assigned to receive enalapril (10 mg twice a day). Notably, although valsartan was given as maximal dosing, the dose of enalapril is half the maximum dose recommended by the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and Heart Failure Society of America.

The rest of the article remains unchanged.

The online version of the original article can be found at <https://doi.org/10.1007/s10557-018-6830-x>

✉ Vinay Prasad
prasad@ohsu.edu

- ¹ School of Medicine, Oregon Health & Science University, Portland, OR, USA
- ² Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
- ³ Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland, OR, USA
- ⁴ Center for Health Care Ethics, Oregon Health & Science University, Portland, OR, USA